U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07854561) titled 'Combination Therapy of Romiplostim and Erythropoiesis-stimulating Agents' on Sept. 28.
Brief Summary: The goal of this Phase 2 clinical trial is to learn if adding romiplostim to standard erythropoiesis-stimulating agent (ESA) therapy is safe and tolerated in adults with chronic kidney disease who are on hemodialysis and have anemia that has not responded well to ESAs. The study will mainly check platelet counts and side effects. The main questions it aims to answer are:
How many participants keep platelet counts within a normal range during and after treatment?
How many participants have platelet counts that rise above the normal ...